Research programme: antibodies - OstriGen

Drug Profile

Research programme: antibodies - OstriGen

Latest Information Update: 15 Dec 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator OstriGen
  • Developer Kyoto Prefectural University of Medicine; Massachusetts General Hospital; OstriGen; United States Army Medical Research Institute of Infectious Diseases
  • Class Antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cholera; Clostridium infections; Diarrhoea; Ebola virus infections; Escherichia coli infections; Norovirus infections; Salmonella infections; Shigella infections; Zika virus infection

Most Recent Events

  • 05 Dec 2016 Preclinical trials in Diarrhoea in Mozambique (PO)
  • 05 Dec 2016 Preclinical trials in Zika virus infection, Shigella infections, Salmonella infections, Norovirus infections, Escherichia coli infections, Ebola virus infections, Clostridium infections, and Cholera in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top